Journal
Clinical Cancer Research
Publication Date
12-16-2024
Volume
30
Issue
24
First Page
5601
Last Page
5611
Document Type
Open Access Publication
DOI
10.1158/1078-0432.CCR-23-3883
Rights and Permissions
Lakhani NJ, Papadopoulos KP, Johnson ML, Park H, Wang D, Yap TA, Dowlati A, Maki RG, Ulahannan S, Lynce F, Kelly K, Williamson S, Malhotra J, Chen S, Gonzalez Ortiz A, Jankovic V, Paccaly A, Masinde S, Mani J, Lowy I, Gullo G, Sims T, Kroog G. First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies. Clin Cancer Res. 2024 Dec 16;30(24):5601-5611. doi: 10.1158/1078-0432.CCR-23-3883 This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. ©2024 The Authors; Published by the American Association for Cancer Research
Recommended Citation
Lakhani, Nehal J; Park, Haeseong; and et al., "First-in-human dose-escalation study of fianlimab, an antilymphocyte activation gene-3 antibody, with cemiplimab in patients with advanced malignancies." Clinical Cancer Research. 30, 24. 5601 - 5611. (2024).
https://digitalcommons.wustl.edu/oa_4/4633
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
